Maxim Group Downgrades TrovaGene (TROV) to Hold; Capital Raise Needed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results
November 9, 2017 10:33 AM ESTSAN DIEGO, Nov. 9, 2017 /PRNewswire/ --Â Trovagene, Inc. (NASDAQ:Â TROV), a clinical-stage precision medicine biotechnology company, today announced company highlights and financial results for the third quarter ended September 30, 2017. The company is issuing this press release in lieu of conducting a conference call.
"We are excited by our continued clinical research advancement of PCM-075, our oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor,"... More
